The Rising Cost of Lung Cancer Therapies: What Are the Global Implications?

The Future Is Now: Pathology Is Going Digital

Histologic Evaluation of Lung Cancer Invasion: More Difficult Than Meets the Eye

Recurrence Remains a Risk Even for Patients Diagnosed via Screening

New Data Support Continued Use of IASLC Staging Model for Mesothelioma

Proposed Criteria for Tumor Invasion Align with Clinical Factors, Offer Better Predictability, Study Finds

Benefit to Pembrolizumab Observed in Previously Treated Malignant Pleural Mesothelioma Irrespective of PD-L1 Status

Treatment of Immunotherapy-Related Ophthalmic Toxicities: An Interview With Dr. Asim V. Farooq

Understanding and Targeting SCLC

KRAS: Old Target, New Hope

Molecular Resistance Mechanisms to EGFR, ALK, and ROS1 TKIs

Approval of Combination Ipilimumab and Nivolumab for Mesothelioma: What Happens Now?